Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Giles, F J, Abruzzese, E, Rosti, G, Kim, D-W, Bhatia, R, Bosly, A, Goldberg, S, Kam, G L S, Jagasia, M, Mendrek, WVolume:
24
Année:
2010
Langue:
english
Pages:
3
DOI:
10.1038/leu.2010.110
Fichier:
PDF, 148 KB
english, 2010